Coronavirus Update: Trial Of Lilly's Antibody Is Next To Be Paused

Plus: Hyperimmune Globulin Trial Launched

NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.  

NIH
The ACTIV-3 Trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

A study of Eli Lilly’s monoclonal antibody Ly-CoV555 in combination with Gilead Sciences’s Veklury (remdesivir) is the latest COVID-19 trial to be paused for safety concerns.

The US National Institute of Allergy and Infectious Disease’s ACTIV-3 trial is part of the agency’s master protocol for assessing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category